Accuray Announces Results for First Quarter Fiscal 2010

October 29, 2009 at 4:10 PM EDT

SUNNYVALE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today financial results for the first quarter of fiscal year 2010, ended September 30, 2009.

For the first quarter of fiscal 2010, Accuray reported total revenue of $50.6 million, compared to the first quarter of fiscal 2009 total revenue of $55.9 million. The revenue component associated with legacy Platinum contracts was $10.2 million for the first quarter of fiscal 2010 versus $18.8 million for the first quarter of fiscal 2009. Revenue excluding revenue associated with Platinum contracts, grew year-over-year 9 percent.

Accuray reported a net loss for the first quarter of fiscal 2010 of $3.3 million, or $0.06 per share, compared to net loss of $3.2 million, or $0.06 per share, during the same period last year. The loss was driven by seasonably low first quarter revenue and lower than normal gross margin during the first quarter. Non-cash, stock based compensation charges were $3.1 million for the first quarter of fiscal 2010.

As previously announced, at the beginning of fiscal year 2010, the Company has refined its definition of backlog, which will include non-contingent orders that fulfill refined criteria. Applying these refined criteria to the backlog as of June 30, 2009 would yield a backlog of $282 million. At the end of the first quarter of fiscal 2010, total backlog was $291 million. During the first quarter of fiscal 2010, nine orders for CyberKnife® Robotic Radiosurgery Systems met the refined criteria and were added to company backlog, which combined with service renewal orders and other ancillary accessory orders yielded a total addition to backlog of $58.8 million. There were no cancellations to backlog in the first quarter, under either the current refined criteria or previous non-contingent definition.

In the first quarter of fiscal 2010, four new CyberKnife Systems were installed, compared to five installations during the same period last year. At the end of the first quarter, the worldwide CyberKnife installation base was 180 units.

"We are pleased that revenue in the first quarter exceeded our earlier guidance," said Euan S. Thomson, Ph.D., Accuray's president and chief executive officer. "While we anticipated a seasonably low first quarter, we expect the remainder of the year to reflect the increasing worldwide demand for full body radiosurgery treatments with the CyberKnife."

Accuray's cash and investment balances at the end of the first quarter of fiscal 2010 totaled $152.6 million, which includes cash and cash equivalents of $33.3 million, restricted cash of $1.5 million, short-term investments of $69.0 million and long-term investments of $48.8 million.

Outlook

The following statement is forward-looking and actual results may differ materially. During fiscal year 2010 Accuray maintains the expectation that revenue will be in the range of $215 million to $230 million. CyberKnife System revenue, which represents approximately two-thirds of total revenue, is driven by customer installation schedules.

Additional Information

Additional information regarding backlog segmentation, which will be discussed during the conference call, is available in the Investor Relations section of the company's Web site at www.accuray.com.

Earnings Call Open to Investors

Accuray will hold a conference call for financial analysts and investors on Thursday, October 29, 2009 at 2:00 p.m. PT / 5:00 p.m. ET. The conference call dial-in numbers are 1-800-638-4930 (USA) or 1-617-614-3944 (International), Conference ID: 97746759. A live webcast of the call will also be available from the Investor Relations section on the company's Web site at www.accuray.com. In addition, a recording of the call will be available by calling 1-888-286-8010(USA) or 1-617-801-6888 (International), Conference ID number: 79365074, beginning at 5:00 p.m. PT / 8:00 p.m. ET, October 29, 2009 and will be available through November 1, 2009. A webcast replay will also be available from the Investor Relations section of the company's Web site at www.accuray.com from approximately 5:00 p.m. PT / 8:00 p.m. ET today through Accuray's release of its results for the second quarter of fiscal 2010, ending December 31, 2009.

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 70,000 patients worldwide and currently 180 Systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

This press release contains forward-looking statements, including those concerning Accuray's expectations about revenue for fiscal year 2010, the portion of revenue attributable to CyberKnife system revenue, realization of backlog, customer installation schedules, and service activity. Forward looking statements involve risks and uncertainties that may lead to actual results varying materially from the forward looking statements. Accordingly, investors are cautioned not to place undue reliance on such statements. Many factors could cause actual performance or results to differ materially from these forward looking statements, including, but not limited to the uncertainties associated with the medical device industry; variability of installation and sales cycle including customer financing and construction delays; changes in the regulatory environment, including reimbursement for CyberKnife procedures; market acceptance of products; and the impact of competition. These and other risks are discussed under the heading "Risk Factors" in our report on Form 10-K for the 2009 fiscal year as well as our quarterly report on Form 10-Q, for the first quarter of fiscal year 2010, both of which have been filed with the Securities and Exchange Commission. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information.




                               Accuray Incorporated
              Unaudited Condensed Consolidated Statements of Operations
                        (in thousands, except per share data)

                                                Three months ended
                                                ------------------
                                          September 30,        September 27,
                                              2009                 2008
                                          -------------      -------------
    Net revenue:
     Products                                 $30,346              $37,455
     Shared ownership program                     481                1,036
     Services                                  19,654               15,907
     Other                                         94                1,459
                                                   --                -----
     Total net revenue                         50,575               55,857
    Cost of revenue:
     Cost of products                          14,651               14,744
     Cost of shared ownership program             321                  262
     Cost of services                          13,920               11,185
     Cost of other                                 64                1,237
                                                   --                -----
     Total cost of revenue                     28,956               27,428
                                               ------               ------
     Gross profit                              21,619               28,429
    Operating expenses:
     Selling and marketing                      8,649               13,480
     Research and development                   7,662                8,754
     General and administrative                 8,930               10,433
                                                -----               ------
     Total operating expenses                  25,241               32,667
                                               ------               ------
    Loss from operations                       (3,622)              (4,238)
    Interest and other income, net                485                1,113
                                                  ---                -----
    Loss before provision for income taxes     (3,137)              (3,125)
    Provision for income taxes                    139                   54
                                                  ---                   --
    Net loss                                  $(3,276)             $(3,179)
                                              =======              =======

    Net income per common share, basic
     and diluted:
     Basic                                     $(0.06)              $(0.06)
     Diluted                                   $(0.06)              $(0.06)
    Weighted average common shares
     outstanding used in computing net
     income per share:
     Basic                                     56,713               54,625
     Diluted                                   56,713               54,625
    Cost of revenue, selling and
     marketing, research and
     development, and general and
     administrative expenses include
     stock-based compensation charges
     as follows:
     Cost of revenue                             $231                 $632
     Selling and marketing                       $808               $1,045
     Research and development                    $648                 $782
     General and administrative                $1,418               $2,512




                              Accuray Incorporated
                 Unaudited Condensed Consolidated Balance Sheets
                        (in thousands, except share amounts)

                                                    September 30,  June 27,
                                                         2009        2009
                                                         ----        ----
    Assets
    Current assets:
     Cash and cash equivalents                        $33,340     $36,835
     Restricted cash                                    1,498         527
     Short-term marketable securities                  68,983      64,634
     Accounts receivable, net of allowance for
      doubtful accounts of $24 at September
      30, 2009 and $484 at June 27, 2009               30,305      36,427
     Inventories                                       25,679      28,909
     Prepaid expenses and other current assets          7,896       6,186
     Deferred cost of revenue-current                  18,166      18,984
                                                       ------      ------
       Total current assets                           185,867     192,502
                                                      -------     -------
    Long-term marketable securities                    48,757      57,252
    Property and equipment, net                        14,061      15,066
    Goodwill                                            4,495       4,495
    Intangible assets, net                                582         668
    Deferred cost of revenue-noncurrent                 2,369       2,933
    Other assets                                        1,498       1,470
                                                        -----       -----
       Total assets                                  $257,629    $274,386
                                                     ========    ========
    Liabilities and stockholders' equity
    Current liabilities:
     Accounts payable                                  $8,467     $14,941
     Accrued expenses                                  14,685      16,188
     Customer advances-current                         15,096      13,185
     Deferred revenue-current                          58,169      68,105
                                                       ------      ------
       Total current liabilities                       96,417     112,419
                                                       ------     -------
    Long-term liabilities:
     Long-term other liabilities                          288         288
     Customer advances-noncurrent                           -           -
     Deferred revenue-noncurrent                        6,117       7,777
                                                        -----       -----
       Total liabilities                              102,822     120,484
                                                      -------     -------

    Stockholders' equity
     Preferred stock, $0.001 par value;
      authorized: 5,000,000 shares; no shares
      issued and outstanding.                               -           -
     Common stock, $0.001 par value;
      authorized: 100,000,000 shares; issued:
      59,542,259 and 58,783,159 shares at September
      30, 2009 and June 27,2009, respectively;
      outstanding:  57,405,241 and 56,643,529
      shares at September 30, 2009 and June
      27, 2009, respectively                               57          57
     Additional paid-in capital                       278,136     273,946
     Accumulated other comprehensive income               407         416
     Accumulated deficit                             (123,793)   (120,517)
                                                     --------    --------
       Total stockholders' equity                     154,807     153,902
                                                      -------     -------
       Total liabilities and stockholders'
        equity                                       $257,629    $274,386
                                                     ========    ========



Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Euan Thomson, Ph.D.

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869

SOURCE Accuray Incorporated

Tom Rathjen, Vice President, Investor Relations, +1-408-789-4458, trathjen@accuray.com, or Stephanie Tomei, Senior Manager, Marketing Communications, +1-408-789-4234, stomei@accuray.com, both of Accuray Incorporated